← Back to headlines
BTIG Sees Upside for ImmunityBio Amid Strong ANKTIVA Sales Growth
BTIG analysts are projecting an upside for ImmunityBio, Inc. (IBRX), attributing their positive outlook to strong anticipated sales growth for ANKTIVA in 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
